Patients with severe, advanced cancer who have undergone guideline-based therapy and patients with rare tumors for which no guideline-based therapy exists are admitted.
Conditions
Interventions
Group 1: Documentation of all MTB patients who fulfill the inclusion criteria and for whom consent has been obtained
Sponsors
Zentrum für Personalisierte Medizin, Universitätsklinikum Tübingen
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. the patient has a defined oncological disease/clear access diagnosis 2. the patient should be referred after presentation to an organ-specific tumor board (internal/external) of a tumor center or oncological focus. 3. physical and mental condition and life expectancy justify continued treatment. The patient is clinically qualified for molecular-based therapy. 4. the guideline-compliant therapies have been completed in the foreseeable future. 5. rare and aggressive oncological diseases can be presented earlier. 6. further diagnostics are aimed at therapeutic intervention. 7. capacity to consent 8. documented patient consent
Exclusion criteria
Exclusion criteria: 1. lack of capacity to consent 2. nonage 3. lack of declaration of consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The aim of the project is to establish a registry for the standardized collection and documentation of long-term data of all patients who are discussed in a MTB of the DNPM in the context of clinical care. Among other things, the dnpm:DIP should support patient care in the context of personalized medicine through a more efficient interdisciplinary flow of information in the long term. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Ensuring quality in the prospective documentation of MTB cases with a focus on clinical outcome parameters such as progression-free survival (PFS), PFS ratio, modified PFS ratio, overall survival (OS) and other response assessments (e.g. imaging, therapy resistance) - Follow-up of the implementation of the therapy recommendations made in the MTB - Provision of the collected care data for long-term research/development of new hypotheses and therapeutic approaches - Quality assurance and research into treatment in personalized medicine | — |
Countries
Germany
Outcome results
None listed